By clicking the View/Register Button
you are agreeing that you have read and understood the information on this page.
The diagnosis and management of multiple sclerosis (MS) continue to evolve with the rapid emergence of new agents, new diagnostic criteria, and the identification of MRI measures and biomarkers capable of improving disease surveillance. Combined with the continued push for earlier diagnosis and initiation of disease-modifying drug therapy (DMD), MS diagnosis and management is becoming increasingly complex. Clinicians face more treatment choices, making the formulation of optimal DMD therapies increasingly difficult. In addition, patient concerns with DMD side effects, treatment preferences, drug costs, and other issues continue to negatively impact patient acceptance of and adherence to DMD treatments.
This program will review the latest research and clinical management information on DMD therapies, diagnostic MRI measures, and biomarkers, in order to provide neurologists and other MS specialists with the knowledge and skills needed to improve the management and outcomes of patients with MS.
Click here to download the program slides from the live meeting held May 28, 2014 at the Hilton Anatole, Dallas, TX, during the 2014 Cooperative Meeting of the Consortium of MS Centers (CMSC) and the Americas Committee for Treatment and Research in MS (ACTRIMS).
Suhayl Dhib-Jalbut, MD
Professor and Chairman
Department of Neurology
Rutgers-Robert Wood Johnson Medical School
Chief, Neurology Service
Robert Wood Johnson University Hospital
New Brunswick, NJ
Suhayl Dhib-Jalbut, MD is Professor and Chairman of the Department of Neurology at Rutgers-Robert Wood Johnson Medical School, and Chief of Neurology at the Robert Wood Johnson University Hospital. He is also Director of the RWJ Center for Multiple Sclerosis (MS).
Dr. Dhib-Jalbut graduated Alpha-Omega-Alpha from the American University of Beirut in Lebanon and completed his neurology training at the University of Cincinnati. He then joined the National Institutes of Health (NIH) in Bethesda, MD, where he specialized in MS and neuroimmunology. Dr. Dhib-Jalbut joined the faculty of the University of Maryland in Baltimore in July 1990 and established a research program in MS before his recruitment to Robert Wood Johnson Medical School in 2003.
Dr. Dhib-Jalbut's research, which has been funded by the NIH, the National MS Society, and industry sources, includes studies of how MS therapies work, biomarkers of treatment response in MS, and neuroprotective gene therapy. Dr. Dhib-Jalbut has published more than 100 manuscripts in the scientific literature. He served as Associate Editor for the Journal of Neuroimmunology. He currently serves on the Editorial Boards of JICR and MS International. He served on several national and international scientific committees, including Chairmanship of the Scientific Committee for the World Congress on MS in 2008. Dr. Dhib-Jalbut has been on the Best Doctors in America list since 2009 and has received several awards and recognitions. Most recently he was awarded the Norman H. Edelman clinical science mentoring award at Rutgers, the Medical Excellence Award by the National MS Society NJ Metro Chapter, and the Edward Ill Award for Excellence in Clinical Research in the State of New Jersey. Dr. Dhib-Jalbut currently serves as President of the Americas Committee for Treatment and Research in MS (ACTRIMS).
Clyde E. Markowitz, MD
Chief, MS Section
Director, MS Center
Associate Professor of Neurology
Perelman School of Medicine
University of Pennsylvania
Clyde E. Markowitz, MD is Director of the MS Center at the Hospital of the University of Pennsylvania, and is an Associate Professor of Neurology at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. He earned his medical doctorate from the Columbia University College of Physicians and Surgeons. He also completed a residency, postdoctoral research, and clinical fellowship at the Neurological Institute at Columbia University College of Physicians and Surgeons in New York.
His expertise is in the field of multiple sclerosis and is involved with many clinical trials developing new compounds for the treatment of MS. His research interests include utilization of new MRI techniques to study the pathogenesis of MS, vision outcome measures in MS, and immunology of MS. He has held the position of Chairman of the Clinical Advisory Committee for the Delaware Valley Chapter of the National Multiple Sclerosis Society. Dr. Markowitz is the author or co-author of a number of publications, and he serves as an ad hoc reviewer for Multiple Sclerosis, Annals of Neurology, Archives of Neurology, Journal of the Neurological Sciences, Neuro-Rehabilitation, Neural Repair, Journal of Clinical Immunology, and The Consultant. Dr. Markowitz is a member of the American Academy of Neurology and he is certified by the National Board of Medical Examiners and the American Board of Psychiatry and Neurology. His work has been published several times in journals, such as Annals of Neurology and Neurology.
Aaron E. Miller, MD
Professor of Neurology
Medical Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, NY
Aaron E. Miller, MD is Professor of Neurology at Mount Sinai School of Medicine and Medical Director at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis. He is widely recognized for his preeminence as an MS clinician and thought leader.
Dr. Miller graduated from Brandeis University in 1964 and received his medical doctorate from New York University School of Medicine in 1968. Following his residency in neurology at the Albert Einstein College of Medicine, he received additional postdoctoral training in neurovirology and immunology at the Johns Hopkins University School of Hygiene and Public Health and at Einstein. During this time, he was the recipient of a fellowship from the National MS Society. In March, 2004, Dr. Miller assumed the position of Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Mount Sinai School of Medicine. For 23 years prior to that, he headed the Division of Neurology at Maimonides Medical Center in Brooklyn, NY, where he continues to serve as Co-director of the MS Care Center.
Dr. Miller has been the Chief Medical Officer of the National MS Society since October 2001 and served as Chairman of the National Medical Advisory Board of the NMSS from 2001-2009. He has been a member of the NMSS Board of Directors since 2003. He was Chairman of the Clinical Advisory Committee of the New York Chapter of the NMSS from 1991-2004, Chairman of the Professional Education Committee of the NMSS, and Past President of the Consortium of MS Centers. He was the first Chairman of the Multiple Sclerosis section of the American Academy of Neurology. He has participated in numerous clinical trials of new treatments for MS.
Dr. Miller is active in the American Academy of Neurology and serves as a member of the Board of Directors. He was Editor of Continuum, their bimonthly continuing education publication, from 2003-2012 and continues to serve as Editor of Continuum Audio. He has been a member of the Education Committee and the Meeting Management Committee. From 1997-2003, he was Co-chairman of the Education Committee and Chairman of the Annual Meeting Subcommittee. Dr. Miller has served as the Principal Investigator for many clinical trials in MS and has been a member of many data and safety monitoring boards. He is the co-author of 2 books on MS and related disorders and has published many peer-reviewed articles and book chapters.
This activity is intended for MS specialists, neurologists, and other health care professionals who manage patients with MS.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Employ newer MRI criteria to improve the early diagnosis of MS
- Select effective DMD therapies earlier in the course of MS
- Describe the mechanisms of action and efficacy and safety profiles of current and emerging DMD therapies in MS
- Develop patient-tailored therapies that optimize adherence, increase effectiveness, and improve individual patient outcomes
- Apply evidence from recent diagnostic and prognostic biomarker studies to improve the monitoring of disease activity and response to DMD therapy in MS
Physicians – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Nurses – Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Physicians – The Potomac Center for Medical Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, the post-test, evaluation, please email firstname.lastname@example.org.
Nurses – This educational activity for 1.25 contact hours is provided by Global Education Group. For information about the nursing accreditation of this program, please contact Global at email@example.com or 303-395-1782.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Suhayl Dhib-Jalbut, MD: Consultant: AbbVie, Bayer, Novartis, Serono, Teva; Grant Support: Novartis, Teva
Clyde E. Markowitz, MD: Consultant: Bayer Healthcare, Biogen Idec, EMD Serono, Genentech, Genzyme, Novartis, Roche, Teva
Aaron E. Miller, MD: Consultant: Acorda Therapeutics, Accordant Health Services (Caremark), Biogen Idec, EMD Serono, Genzyme/Sanofi-Aventis, GlaxoSmithKline, Novartis, Nuron Biotech; Research Support: Acorda Therapeutics, Biogen Idec, Genentech, Genzyme/Sanofi-Aventis, Novartis, Roche, Questcor
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Matthew Horn, MD; Blair St. Amand; Jay Katz, CCMEP; Amanda Glazar, PhD; Ashley Marostica, MSN, RN; Dana Simpler, MD: Nothing to disclose
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test by obtaining a score of 71%. Participant is allowed to take the post-test three times.
JOINTLY PROVIDED BY
|Potomac Center for Medical Education and Rockpointe
Global Education Group
This activity is supported by an educational grant from Teva Neuroscience.
By clicking the View/Register Button
you are agreeing that you have read and understood the information on this page.